- Home
- MAC vs DNTH Comparison
MAC vs DNTH Comparison
Compare MAC & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAC | DNTH |
|---|---|---|
| Founded | 1964 | 2015 |
| Country | United States | United States |
| Employees | 2845 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 5.9B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MAC | DNTH |
|---|---|---|
| Price | $25.54 | $89.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 18 |
| Target Price | $26.73 | ★ $139.25 |
| AVG Volume (30 Days) | ★ 3.0M | 919.3K |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.65% | N/A |
| EPS Growth | ★ 11.36 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,013,983,000.00 | $2,036,000.00 |
| Revenue This Year | N/A | $36.90 |
| Revenue Next Year | $6.76 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.43 | N/A |
| 52 Week Low | $16.03 | $34.29 |
| 52 Week High | $26.68 | $117.88 |
Technical Indicators
Market Signals| Indicator | MAC | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 65.33 | 60.24 |
| Support Level | $24.97 | $89.21 |
| Resistance Level | $25.97 | $91.36 |
| Average True Range (ATR) | 0.58 | 4.01 |
| MACD | 0.13 | 1.82 |
| Stochastic Oscillator | 85.49 | 85.32 |
Price Performance
Historical ComparisonAbout MAC Macerich Company (The)
Macerich invests in premium mall assets. The company owns 28 regional malls in its consolidated portfolio and nine regional malls in its unconsolidated portfolio along with a power center and six other real estate assets. The company's total portfolio has 39.9 million square feet of gross leasable area and averaged $199 in sales per square foot over the 12 months ended in June 2026.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.